Results 151 to 160 of about 1,571,981 (263)

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

A comparison of in-the-moment and retrospective patient-reported outcome measures in advanced cancer. [PDF]

Support Care Cancer
Geeraerts J, de Nooijer K, Pivodic L, Crombez G, Decoster L, Fontaine C, Joris S, Naert E, De Ridder M, Van den Block L.   +9 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Patient-reported outcome measures in patients with systemic lupus erythematosus with or without concurrent fibromyalgia. [PDF]

Lupus
Gold HT, Li Y, Anthopolos R, Buyon JP, Masson M, Cohen B, Gutowski E, Saxena A, Belmont HM, Tseng CE, Corbitt K, Izmirly PM.   +11 more
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Systematic review of patient-reported outcome measures for opioid use disorder recovery. [PDF]

Addiction
Pytell JD, Pales D, Simon C, Beaudoin J, Osman AMY, Svoboda E, Christine PJ, Matlock D, Schwartz R, Binswanger IA.   +9 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Readability Analysis of Commonly Cited Patient-Reported Outcome Measures in the Orthopaedic Joint Literature. [PDF]

Arthroplast Today
Uppal H, Garcia D, Rezzadeh K, Sahai N, McGinniss A, Emami A, Rifai A.   +6 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

BMI and its association with patient-reported outcome measures following revision hip surgery. [PDF]

Bone Jt Open
Baumber R, Mehmood A, McCulloch R, Pereira SMP, Warwick E, Hart A, Moonesinghe SR, PQIP delivery team, PQIP collaborative, PQIP delivery team and collaborative, PQIP Delivery Team, Ramani Moonesinghe S, Wagstaff D, Bedford J, Sahni A, McGuckin D, Gilhooly D, Santos C, Wilson J, Martin P, Singleton G, Edwards K, Vindrola-Padros C, Warnakulasuriya S, Dorey J, Leemans I, Martinez D, Lourtie J, Baumber R, Dorey J, Swift A, Jackson A, Belete M, Warwick E, Argent M, Brooks R, Fulop N, Brent A, Williams K, Grocott M, Mythen M, Olive D, Taylor C, Drake S, Swart M, Bougeard AM, Bedford M, Vallance A, Singh P, Vohra R, Ignacka A, Tucker O, Aresu G, Cripps M, Ellicott H, Samuel K, Chazapis M, Hunt AF, Lusby E, Durrand J, Weerasuriya S, PQIP Collaborative, Batchelor A, Snowden C, Murray D, Evans E, Vaux E, Abercrombie J, McGhie J, Dhesi J, Clark T, Crossley A, McGrath J, Digner M, Hamilton M, Hill R, Shinde S, Brett S.   +77 more
europepmc   +1 more source